Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Basilea Pharmaceutica AG

Basilea reports strong 2024 half-year results and significantly increases full-year revenue and profit guidance
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea partners oncology drug candidate lisavanbulin with Glioblastoma Foundation
From Basilea Pharmaceutica AG
Via GlobeNewswire
Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports presentation of new data for ceftobiprole (Zevtera®) at ESCMID Global 2024
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea awarded CARB-X grant to develop recently acquired novel class of antibiotics
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces US FDA approval of antibiotic ZEVTERA® (ceftobiprole medocaril) for three indications
From Basilea Pharmaceutica AG
Via GlobeNewswire
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers milestone payment to Basilea
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports strong 2023 full-year results with profitability significantly above guidance, whilst substantially expanding the R&D portfolio
From Basilea Pharmaceutica AG
Via GlobeNewswire
Cresemba® sales in Latin America trigger first sales milestone payment to Basilea
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces acquisition of preclinical antibiotics program from Spexis
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea provides portfolio status update
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces accelerated loan repayment
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces that FDA approves expanded use of antifungal Cresemba® (isavuconazole) in the United States in children with invasive aspergillosis and invasive mucormycosis
From Basilea Pharmaceutica AG
Via GlobeNewswire
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers third sales milestone payment for the region from Pfizer this year
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces acquisition of fosmanogepix, a phase-3-ready broad-spectrum antifungal
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces exclusive license and option agreement for potential first-in-class clinical-stage antibacterial agent
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces acquisition of novel clinical-stage antifungal for treatment of Aspergillus mold infections
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports new data for ceftobiprole (Zevtera®) presented at US IDWeek Congress 2023
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces FDA acceptance of New Drug Application for antibiotic ceftobiprole
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces New England Journal of Medicine publication of phase 3 data on ceftobiprole for the treatment of Staphylococcus aureus bacteremia
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports strong revenue and profit growth in first half-year 2023
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces submission of a New Drug Application to the US Food and Drug Administration for its antibiotic ceftobiprole
From Basilea Pharmaceutica AG
Via GlobeNewswire
Continued strong Cresemba® (isavuconazole) sales by Pfizer trigger USD 26 million sales milestone payments to Basilea
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea shareholders approve all proposals of the board of directors at the annual general meeting
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea provides update on New Drug Application to the US Food and Drug Administration for antibiotic ceftobiprole
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea announces CHF 5 million milestone payment from Asahi Kasei Pharma for antifungal Cresemba® (isavuconazole) in Japan
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports strong financial results 2022 based on successful implementation of new strategy
From Basilea Pharmaceutica AG
Via GlobeNewswire
Continued strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers second sales milestone payment to Basilea from Pfizer
From Basilea Pharmaceutica AG
Via GlobeNewswire
Basilea reports preliminary operating profit for 2022, significantly above guidance
From Basilea Pharmaceutica AG
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.